Clarius Group LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 10.5% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 29,092 shares of the company’s stock after selling 3,407 shares during the period. Clarius Group LLC’s holdings in Johnson & Johnson were worth $4,509,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Glassy Mountain Advisors Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $35,000. GW&K Investment Management LLC purchased a new position in Johnson & Johnson during the 4th quarter worth approximately $35,000. Dark Forest Capital Management LP increased its holdings in shares of Johnson & Johnson by 1,044.4% in the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after acquiring an additional 188 shares during the period. Retirement Financial Solutions LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth $40,000. Finally, Ruedi Wealth Management Inc. purchased a new position in Johnson & Johnson during the 4th quarter worth $42,000. 67.57% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
JNJ has been the topic of a number of research reports. Raymond James lowered their price target on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday, April 19th. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. StockNews.com started coverage on Johnson & Johnson in a report on Thursday, May 18th. They set a “strong-buy” rating for the company. Atlantic Securities cut their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Finally, Credit Suisse Group boosted their price target on shares of Johnson & Johnson from $168.00 to $170.00 in a research note on Friday, May 5th. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $171.57.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Free Report) last issued its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter last year, the business posted $2.67 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd were paid a dividend of $1.19 per share. The ex-dividend date of this dividend was Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a yield of 2.88%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s payout ratio is currently 99.58%.
Insider Activity
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- MarketBeat Week in Review – 6/26 – 6/30
- Tesla: Can Downgrades Make Sense After A 170% Rally?
- Buffett’s Berkshire Increases Stake In Occidental Petroleum (OXY)
- Rally Gains Momentum On Soft PCE Data
- Bank of America, JPMorgan, Goldman Sachs Set For Dividend Growth?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
